Study S001960

Multicenter, Randomised, Placebo-controlled, Double Blinded, Parallel Arm Proof-of-concept Trial of Lixisenatide in Patients With Early Parkinson's Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03439943
Acronym: LixiPark
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 156
Start: 2018-06-13
Primary completion: 2021-04-15
Lead sponsor: University Hospital, Toulouse
Conditions: Parkinson Disease
Interventions: DRUG:Lixisenatide; DRUG:placebo
Results posted: FALSE

Registered primary outcomes

Change from baseline to end-point (M12) in the MDS-UPDRS III motor (Movement Disorder Society-Unified Parkinson's disease rating scale) [12 month]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007740	Trial of Lixisenatide in Early Parkinson's Disease. Meissner WG, The New England journal of medicine	2024	Randomized trial	PMID 38598572 DOI	cites ClinicalTrials.gov:NCT03439943; registry reference RESULT:38598572